https://youtu.be/iyfWB9U9Odw In a recent conversation with Big Biz TV, CEO Lori Woods talked with Big Biz TV about Isoray’s important role in the war on cancer and the difference Cesium-131 internal radiation therapy is making in treating prostate and hard to treat...
Patients with Newly Diagnosed Malignant Brain Tumors Now Eligible for Surgically Targeted Radiation Therapy TEMPE, Ariz. -- GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that the U.S. Food and...
After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and patient-reported evidence suggest that Cesium-131 delivers equivalent to, or superior outcomes compared to Iodine and...
2017 saw the publication and dissemination of multiple new studies, including long-term results, and guidelines for prostate cancer treatment. Yet as the year passed by, we were surprised to discover that many clinicians remained unaware of the data and its ability to...
Study Demonstrates 100% Freedom from Local Progression Rate & 0% Rate of Radionecrosis RICHLAND, Wash., June 20, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
The following article originally appeared in the Winter/Spring 2017 MicroCap Review Magazine. A small company in Richland, WA is dedicated to making a difference in the lives of patients diagnosed with different forms of cancer. Isoray Medical, Inc. [NYSE MKT:ISR] has...